Free Fatty Acid Receptor 4 - Pipeline Review, H2 2016 Featuring Advinus Therapeutics, Dompe Farmaceutici, GSK & Sancilio & Company - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Free Fatty Acid Receptor 4 - Pipeline Review, H2 2016" report to their offering.

Free Fatty Acid Receptor 4 pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Free Fatty Acid Receptor 4 is a G protein-coupled receptor (GPR) encoded by FFAR4 gene. It acts as receptor for medium and long-chain free fatty acids (FFAs). It acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G (q)/G (11)-coupled pathway. It mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. It mediates the taste of fatty acids.

The report 'Free Fatty Acid Receptor 4 - Pipeline Review, H2 2016' outlays comprehensive information on the Free Fatty Acid Receptor 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 4 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Preclinical and Discovery stages are 1 and 4 respectively.

Key Topics Covered:

  1. Introduction
  2. Free Fatty Acid Receptor 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Free Fatty Acid Receptor 4 - Overview
  5. Pipeline Products for Free Fatty Acid Receptor 4 - Comparative Analysis
  6. Free Fatty Acid Receptor 4 - Therapeutics under Development by Companies
  7. Free Fatty Acid Receptor 4 - Therapeutics under Investigation by Universities/Institutes
  8. Free Fatty Acid Receptor 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Free Fatty Acid Receptor 4 - Products under Development by Companies
  13. Free Fatty Acid Receptor 4 - Products under Investigation by Universities/Institutes
  14. Free Fatty Acid Receptor 4 - Companies Involved in Therapeutics Development
  • Advinus Therapeutics Ltd
  • Dompe Farmaceutici S.p.A.
  • GlaxoSmithKline Plc
  • Sancilio & Company, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/75psp3/free_fatty_acid

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs